文献速递临床试验与 GCP

环泊酚麻醉诱导下瑞芬太尼抑制气管插管反应的EC90:偏向硬币设计剂量探索试验的研究方案

The EC90 of remifentanil for inhibiting endotracheal intubation responses under anesthesia induction with ciprofol: study protocol for a dose-finding trial with the biased-coin design.
PubMed 文献 · Trials · 2024-08-23

本研究为前瞻性序贯分配剂量探索试验,纳入ASA I-II级择期手术患者,在环泊酚麻醉诱导下采用偏向硬币设计上下序贯法(BC-UDM)确定瑞芬太尼抑制气管插管心血管反应的90%效应室浓度(EC90)。插管心血管反应阳性定义为平均动脉压或心率较基线升高15%以上,EC90及90%置信区间采用R-Foundation中心等渗回归和合并相邻违例者算法结合自举法估计。

要点

  • 研究采用BC-UDM确定环泊酚麻醉诱导下瑞芬太尼抑制插管反应的EC90。
  • 插管心血管反应阳性定义为MAP或HR较基线升高15%以上。
  • EC90及90%CI采用中心等渗回归和合并相邻违例者算法结合自举法估计。

核心结论

  • 本研究旨在展示在麻醉指数(Ai)引导的环泊酚麻醉下,采用BC-UDM确定瑞芬太尼减弱气管插管交感反应的EC90,可能有助于减轻气管插管的心血管反应。

研究设计与样本

  • 前瞻性序贯分配剂量探索试验,纳入ASA I-II级择期手术患者,接受瑞芬太尼效应室浓度(Ce)靶控输注(TCI),随后给予环泊酚和罗库溴铵进行麻醉。
  • 采用偏向硬币设计上下序贯法(BC-UDM),根据前一位患者的气管插管心血管反应确定下一位患者的瑞芬太尼Ce。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 气管插管心血管反应阳性定义为平均动脉压(MAP)或心率(HR)较基线值升高15%以上。
  • EC90及90%置信区间(90%CI)采用R-Foundation中心等渗回归和合并相邻违例者算法结合自举法估计。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tracheal intubation may cause significant hemodynamic responses. Many drugs have been shown to be effective in modifying these cardiovascular responses, including remifentanil, fentanyl, sufentanil, and alfentanil. However, the 90% effect-site concentration (EC90) of remifentanil required to control cardiovascular responses to tracheal intubation when combined with ciprofol remains unclear. The purpose of this study was to determine the EC90 of remifentanil inhibiting cardiovascular responses to tracheal intubation during anesthesia induction with ciprofol using biased-coin design up-and-down sequential method (BC-UDM). METHODS: This is a prospective sequential allocation dose-finding study. American Society of Anesthesiologists physical status (ASA) I-II elective surgical patients receiving target-controlled infusion (TCI) of remifentanil effect-site concentration (Ce), followed by ciprofol and rocuronium for anesthesia, were enrolled. The cardiovascular response to tracheal intubation was defined as positive when mean arterial pressure (MAP) or heart rate (HR) is 15% higher than the baseline value. Using the BC-UDM, the Ce of remifentanil was determined based on the cardiovascular response to tracheal intubation of the previous patient. The EC90 and 90% confidence intervals (90% CIs) were estimated by R-Foundation centered isotonic regression and the pooled adjacent violators algorithm with bootstrapping. DISCUSSION: The results of this study sought to demonstrate EC90 of remifentanil blunting sympathetic responses to tracheal intubation during anesthesia index (Ai)-guided ciprofol anesthesia using BCD-UDM. It may help to minimize the cardiovascular responses to tracheal intubation. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300078275. Registered on December 3, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guo J, Xu F, Li L, et al. The EC90 of remifentanil for inhibiting endotracheal intubation responses under anesthesia induction with ciprofol: study protocol for a dose-finding trial with the biased-coin design. Trials. 2024. PMID: 39180100. doi:10.1186/s13063-024-08397-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。